Dr. Guillermo Torre-Amione reports

CARDIOL THERAPEUTICS REPORTS RESULTS OF 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

Cardiol Therapeutics Inc. has released the results from its annual general meeting of shareholders held virtually by live audio webcast on June 24, 2026. Shareholders voted overwhelmingly in favour of all management resolutions proposed in the company's management information circular dated May 7, 2026.

Resolutions proposed and approved at the AGM were:

• The election of the following directors for the ensuing year: Dr. Guillermo Torre-Amione, David Elsley, Chris Waddick, Teri Loxam, Dr. Timothy Garnett, Jennifer Chao, Peter Pekos and Colin Stott;
• The appointment of BDO Canada LLP as auditor of the company for the current fiscal year and the authorization of the directors of the company to fix the remuneration to be paid to the auditor.

The results of the voting on the election of directors are as follows.

A webcast of the AGM will be accessible under "Events & Presentations" in the investors section of the Cardiol website.

About Cardiol Therapeutics Inc.

Cardiol Therapeutics is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The company's lead small-molecule drug candidate, CardiolRx, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis and heart failure.

The Maveric program is evaluating CardiolRx for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits and hospitalizations. The program comprises the completed phase II Maveric pilot study (NCT05494788) and the continuing pivotal phase III Maveric trial (NCT06708299). The U.S. FDA (Food and Drug Administration) has granted orphan drug designation to CardiolRx for the treatment of pericarditis, including recurrent pericarditis.

The Archer program also studied CardiolRx in acute myocarditis -- an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed phase II Archer study (NCT05180240), which evaluated the safety, tolerability and efficacy of CardiolRx in this patient population.

The company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure -- a leading cause of death and hospitalization in the developed world, with associated health care costs in the United States exceeding $30-billion (U.S.) per year.

We seek Safe Harbor.